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or the elderly who are most affected by inﬂuenza, and to
ncrease vaccine coverage in younger adults. The intrader-
al route of vaccination provides a direct and potentially
ore efﬁcient access to the immune system. An ID TIV
as developed with a unique, convenient microinjection
ystem, and 2 dosage presentations speciﬁcally for elderly
nd younger adults (respectively 15g or 9g hemagglu-
inin/strain/dose).
Methods: The immunogenicity and safety of the two
resentations of ID TIV have been investigated in sev-
ral large-scale Phase 2 and 3 studies in several European
ountries, Australia and New Zealand. In each study, a
icensed intramuscular TIV, (Vaxigrip®; 15g hemagglu-
inin/strain/dose) was used as a control. Safety evaluation
ncluded documentation of solicited and unsolicited reac-
ions. Hemagglutination inhibition responses were evaluated
n D0 and D21.
Results: Phase 2 studies in more than 2000 subjects aged
8—60 years or >60 years have demonstrated that the 15g
D intradermal vaccination induces higher immune responses
ompared with Vaxigrip against all three strains, as assessed
y D21 GMTs and seroprotection rates. Among younger
dults, the 9g intradermal vaccine was demonstrated to
nduce an equivalent immune response to Vaxigrip.
Safety results showed that both ID vaccine presentations
ere well tolerated. When 18—60 year olds, subjects were
accinated a second time either ID or IM, one year after
heir ﬁrst vaccination, reactogenicity was not enhanced
ompared with that observed after the ﬁrst vaccination.
Conclusion: Using microinjection to deliver antigen via
he less-invasive intradermal route, ID TIV was shown to
licit superior immune responses to conventional vaccine in
lderly adults, and provides an alternative vaccine for adults
hat may encourage increased vaccine uptake.
oi:10.1016/j.ijid.2008.05.088
9.004
rom Immunogenicity to Vaccine Efﬁcacy: Insights from
tatistical and Causal Models
.E. Halloran
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ackground & Objectives: The identiﬁcation of immunolog-
cal surrogate markers of protection against disease plays
key role in the assessment of the efﬁcacy of any vaccine.
he sole identiﬁcation of an appropriate surrogate marker is
owever not sufﬁcient to provide an accurate prediction of
accine efﬁcacy. A statistical model providing a reliable esti-
ation of the relationship between this marker and clinical
rotection is also required. We review analyses and mod-
ls that explore this relationship in the case of inﬂuenza.
e then discuss the application of such models to estimate
he gain in efﬁcacy provided by a novel seasonal inﬂuenza
accine given by intradermal microinjection.
Methods & Principal ﬁndings: Several markers have been
sed to assess the immunogenicity of inﬂuenza vaccines.
nti-haemagglutinin antibodies, measured by the haemag-
lutination inhibition (HI) assay is however the only one for
hich attempts have been made to quantify its relationship
ith protection against clinical inﬂuenza. Seminal analyses
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ocused on the identiﬁcation of an HI titre level that can be
ssociated with either a 50% reduction (1:40) or a 90% reduc-
ion (1:92) in the risk of inﬂuenza. More recently, a model
sing published data from 15 studies, conﬁrmed the signiﬁ-
ant and positive relationship existing between HI titre and
linical protection against inﬂuenza and provided an esti-
ate of the level of protection against inﬂuenza for any
I titer. When applied to immunogenicity data from clinical
rials with an trivalent, inactivate inﬂuenza vaccine given
y intradermal microinjection, this model predicts a gain
n vaccine efﬁcacy of 14% (95% CI: 10—18) compared with
onventional non-adjuvanted inactivated inﬂuenza vaccines
iven intramuscularly.
Conclusions: Statistical models estimating the relation-
hip between HI data and level of protection against
nﬂuenza provide useful information to predict vaccine efﬁ-
acy, particularly for comparing vaccines based on their
mmunological proﬁle.
oi:10.1016/j.ijid.2008.05.089
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.R. Reddy
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pproximately 170 million people world wide are infected
ith Hepatitis C virus (HCV). The therapy of hepatitis C
as gone through various phases of development. In the
arly 90s, therapy was empirical and standard interferon
as given initially for 6 months and then for 12 months. Then
ame along ribavirin, a guanosine analog and an oral drug,
hich administered with interferon improved sustained viro-
ogic response rates and this primarily was achieved by
ecreasing relapse rates. The current standard of care as
herapy for Hepatitis C consists of pegylated interferon-alfa
nd ribavirin. In genotype 1 patients, sustained virologic
esponse rates have been around 40—60% after 48 weeks
f therapy whereas non-1 patients, primarily made up of
enotypes 2 and 3, have an approximate 80% probability
f sustained virology response after 24 weeks of therapy.
lthough treatment duration has traditionally been ﬁxed,
here is a paradigm of virologic response guided therapy
hat has evolved. For rapid virologic responders, charac-
erized as HCV RNA negativity at week 4, reports suggest
hat 12—16 weeks of therapy for genotype 2 patients and 24
eeks of therapy for genotype 1 patients may be adequate.
n contrast, in genotype 1 patients who have a slow response
haracterized by a loss of HCV RNA at week 24, a prolonged
ourse of 72 weeks is the optimal regimen. Despite these
dvances, there is an unmet need for better therapies in the
on-responders, in those with advanced and decompensated
iver disease, in those with a spectrum of special situations
uch as transplantation etc, and those who do not tolerate
nterferon and ribavirin. Thus there is a need for novel ther-
pies with enhanced efﬁcacy, tolerability, and greater ease
f administration.
We now stand at the edge of an exciting phase with
he advent of Speciﬁcally Targeted Antiviral Therapy for
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HCV (STAT-C), wherein orally administered small molecules
can provide targeted activity at speciﬁc points in the viral
life cycle. The ability to target speciﬁc steps of repli-
cation is apparent in the myriad of novel therapies in
research, such as protease inhibitors, nucleoside and non-
nucleoside polymerase inhibitors, glucosidase Inhibitors,
inosine monophosphate dehyrogenase (IMPDH) inhibitors,
and immune modulators (Interferons and their inducers,
toll-like receptor analogues, therapeutic vaccines). Combi-
nation therapies with new small molecules and peg-INF with
or without ribavirin are currently being evaluated. One of
the challenges of STAT-C therapy would be the prevention of
the evolution of drug resistance while enhancing tolerabil-
ity, decreasing treatment duration, and ultimately achieving
higher sustained virologic response rates.
doi:10.1016/j.ijid.2008.05.090
30.003
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Liver complications have emerged as an important cause of
hospitalization and mortality among HIV-infected persons.1
Anti-HCV treatment offers the opportunity to eradicate HCV,
reduce the risk of disease progression and reduce liver-
related deaths. These beneﬁts are signiﬁcant and provide
the justiﬁcation for consideration of HCV treatment in every
HIV-HCV coinfected patient. However, since treatment is not
uniformly effective and is associated with side effects in the
majority of treated patients, the decision to proceed with
treatment requires a careful weighing of risk and beneﬁts
for each patient.
Patients should be on a stable ART regimen for at least
3 months prior to starting HCV treatment. Didanosine (DDI)
is absolutely contraindicated due to high risk of toxicity.2
Stavudine (D4T) and abacavir are relative contraindicated
due to interactions with ribavirin. AZT increases the risk of
anemia and should be avoided if possible.
The treatment of choice is peginterferon alfa (peg-IFN)
and weight-based ribavirin (1000mg daily if <75 kg and
1200mg daily if >75 kg).3 Weight-based ribavirin is recom-
mended for all genotypes, due to the higher rate of relapse
in HCV-HIV coinfected patients compared with HCV monoin-
fected patients. The dose of peginterferon alfa-2a is 180 ug
weekly and of peginterferon alfa-2b is 1.5 ug/kg weekly. The
duration of treatment is 24—48 weeks for genotypes 2 and
3 and 48—72 weeks for genotype 1, 4—6, with the time to
loss of HCV determining the length of treatment. Early viral
kinetics strongly inﬂuences duration of therapy. Shorter
duration may be a consideration in patients achieving a
rapid virologic response (RVR), deﬁned as undetectable HCV
RNA at week 4 of treatment. Longer duration therapy (up to
72 weeks) is a strong consideration in ‘‘slow responders’’.
The most consistently identiﬁed pre-treatment predictors
of SVR are HCV viral load and HCV genotype.4—7 Adherence
is an important factor in achieving SVR in HCV-monoinfected
patients but data in coinfected patients is more
limited.
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Patients labeled as non-responders need to be carefully
valuated to identify those that may beneﬁt from retreat-
ent using optimal doses and duration of current therapies.
he available data indicate that subjects who failed a prior
ourse of suboptimal therapy may achieve SVR but at rates
ower than treatment-naive patients.8 Overall, the chance
VR in previously treated patients is dependent upon the
fﬁcacy of the previous tried regimen.
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IV infected subjects often have a multitude of metabolic
efects. The clinical outcomes associated with these
bnormalities include lipodystrophy, insulin resistance, dys-
ipidemia, nonalcoholic fatty liver disease, accelerated
therosclerosis with both coronary artery disease (CAD)
nd peripheral vascular disease. The development of these
omplications reﬂect a complex interaction between the
atient, the HIV virus, other concomitant infections and
AART therapy. The seriousness of these complications is
nderscored by the rising mortality from non-HIV related
auses in infected subjects. This is particularly important
n males >55 yrs of age where CAD is the leading cause
f death. Subjects with HIV infection are at increased risk
or myocardial infarction and this risk is related to the
se of protease inhibitors (PI). It is however important to
ote that conventional risk factors e.g. smoking are more
mportant determinants of cardiovascular outcomes rather
